An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China - Trial NCT06421740
Access comprehensive clinical trial information for NCT06421740 through Pure Global AI's free database. This phase not specified trial is sponsored by AbbVie and is currently Not yet recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 1000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
AbbVie
Timeline & Enrollment
N/A
May 20, 2024
Jun 30, 2026
Primary Outcome
Number of participants with a dose change,Number of participants with interruption or permanent discontinuation,Number of participants with Upadacitinib drug compliance
Summary
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to
 inflammation of the skin.
 
 Upadacitinib is an approved drug for treating AD. Approximately 1000 adolescents and adult
 participants who are prescribed upadacitinib by their physician in accordance with local
 label will be enrolled in up to 40 sites in China.
 
 Participants will receive oral upadacitinib tablets as prescribed by their physician
 according to their routine clinical practice and local label. Participants will be followed
 up for approximately 12 months.
 
 There is expected to be no additional burden for participants in this trial. Participants
 will attend regular visits during the study at a hospital or clinic according to their
 routine clinical practice.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06421740
Non-Device Trial